---
title: 'Griffith University OEC "3D Nerve Bridge" Trial'
pubDate: 2026-02-13
pdfUrl: "https://assets.beyondparalysis.uk/Griffith%20University%20OEC%20Nerve%20Bridge%20plus%20NervGenn%20291.pdf"
executiveSummary: "A world-first Phase I/IIa clinical trial by Griffith University implanting patients' own olfactory ensheathing cells (OECs) inside a 3D scaffold to repair chronic spinal cord injuries, combined with intensive rehabilitation."
---

### The History: Decades in the Making
The concept of using cells from the nose to repair the spinal cord isn't new, but this trial represents its most advanced evolution.
* **1990s:** Foundational research established that the olfactory system is the only part of the nervous system that continually regenerates throughout adult life.
* **2002 (Portugal):** Dr. Carlos Lima performed early open-label transplants of whole olfactory tissue. While safe, results were mixed, and some patients later developed complications (mucosal cysts) because the grafts weren't purified.
* **2014 (Poland):** The famous case of Darek Fidyka, who regained some walking function after receiving a transplant of olfactory bulb cells combined with a peripheral nerve bridge.
* [cite_start]**2025 (Australia):** The Griffith team launches the first randomized, controlled trial using **purified** OECs in a specialized **3D nerve bridge**, designed to avoid past safety issues and maximize regeneration[cite: 1].

### Key People
* **Prof. James St John:** The lead scientist heading the Clem Jones Centre for Neurobiology and Stem Cell Research. He championed the "3D liquid marble" technique to create the nerve bridges.
* **Prof. Alan Mackay-Sim (Legacy):** The 2017 Australian of the Year whose pioneering work on OECs laid the groundwork for this entire field.
* **Perry Cross:** A C2 quadriplegic and founder of the Perry Cross Spinal Research Foundation, which raised over $5.7M to fund this trial. His advocacy turned the science into a reality.
* **Dr. Michael Redmond:** The neurosurgeon performing the complex implantation surgeries at Gold Coast University Hospital.

### The Story: A Patient's Journey
For a participant in this trial, the commitment is massive. It is not just a surgery; it is a lifestyle overhaul.
1.  **The Harvest:** It begins with a nasal biopsy. Surgeons remove a small piece of the olfactory mucosa high inside the nose.
2.  **The Engineering:** In the lab, technicians purify the Olfactory Ensheathing Cells (OECs) to ensure safety. These cells are then grown into a 3D "rope" or bridge—roughly 1-2cm long—using a proprietary culture method.
3.  **The Implant:** Weeks later, the patient undergoes spinal surgery. The scar tissue on the spinal cord is carefully removed, and the living OEC bridge is placed into the gap.
4.  **The Work:** This is where the story diverges from a "magic pill." Participants must commit to **8 months of high-intensity rehabilitation** (up to 3 hours a day, 5 days a week). The theory is that the cells build the bridge, but the exercise teaches the nerves how to cross it.

### Deep Dive: The Research & Mechanism
**The "Living Scaffolding" Concept**
Unlike simple cell injections which can wash away, this trial uses a solid 3D construct. The OECs are natural "nurse cells"—they normally guide new smell nerves from the nose into the brain. When transplanted into the spinal cord, they:
* Clear away inhibitory debris and scar tissue.
* physically align to form a tunnel that regenerating axons can grow through.
* Remylinate (insulate) damaged nerves to restore conduction.

**Trial Design (The "Gold Standard")**
Uniquely for a surgical trial, this study includes a **control group**.
* **Cohort:** 30 adults with chronic (≥4 months) traumatic SCI (Thoracic or Low Cervical).
* **Split:** 20 receive the transplant + rehab; 10 receive rehab only.
* **Blinding:** Assessors do not know who received the cells, preventing bias in the results.

**Current Status (2026)**
The trial is currently active and recruiting. Early safety reports are positive, with no serious adverse events linked to the implant. Definitive efficacy data (did it restore motor function?) is expected to be analyzed and released around 2028.

### Sources & References
* **Official Clinical Trial Registry:** [NCT03933072 - Autologous Bulbar Olfactory Ensheathing Cells and Nerve Grafts](https://clinicaltrials.gov/study/NCT03933072)  
    *The official government record of the trial design, inclusion criteria, and status.*
* **The Funding Foundation:** [Perry Cross Spinal Research Foundation (PCSRF)](https://www.pcsrf.org.au/)  
    *The main charity funding the trial. Their site contains patient stories and fundraising updates.*
* **Griffith University News:** [World-first clinical trial commences to treat spinal cord injury](https://news.griffith.edu.au/?s=spinal%20cord%20injury)  
    *Official press release from Griffith University detailing the launch of the study.*
* **Key Research Paper (top of page):** *Delivering the goods: the nose-to-brain pathway for drug delivery* (St John et al.)  
    *Academic background on the mechanism of Olfactory Ensheathing Cells (OECs).*

* **Mike's Deep Dive YouTube Video:** [World First Spinal Cord Injury Clinical Trial: OEC "Nerve Bridge" (Griffith University, Australia)](https://youtu.be/Pam3jzLaNaQ)
    *My full video breakdown of the Griffith OEC trial.*
* **Griffith University's Own SCI Video:** [Hope, Science, and Breakthroughs Inside the World-First Spinal Cord Injury Trial](https://www.youtube.com/watch?v=cWwrNDVc7R4)
    *Official video from Griffith University on the trial.*